Retinoic Acid Potentiates the Therapeutic Efficiency of Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs) against Cisplatin-Induced Hepatotoxicity in Rats

被引:6
|
作者
Azzam, Maha M. [1 ]
Hussein, Abdelaziz M. [2 ]
Marghani, Basma H. [1 ,3 ]
Barakat, Nashwa M. [4 ]
Khedr, Mohsen M. M. [5 ]
Abu Heakel, Nabil [1 ]
机构
[1] Mansoura Univ, Mansoura Fac Vet Med, Dept Physiol, Mansoura 35516, Egypt
[2] Mansoura Univ, Mansoura Fac Med, Dept Med Physiol, Mansoura 35516, Egypt
[3] King Salman Int Univ, Fac Vet Med, Dept Biochem Physiol & Pharmacol, South Of Sinaa 46612, Egypt
[4] Mansoura Univ, Urol & Nephrol Ctr, Mansoura 35516, Egypt
[5] Port Said Univ, Fac Sci, Dept Chem, Port Said 42521, Egypt
关键词
cisplatin hepatotoxicity; BM-MSCs; retinoic acid; oxidative stress; NADPH oxidase; apoptosis; INDUCED LIVER-INJURY; TUMOR-NECROSIS-FACTOR; IN-VITRO; OXIDATIVE STRESS; HEPATIC-INJURY; NITRIC-OXIDE; DIFFERENTIATION; HEPATOCYTES; INHIBITION; TOXICITY;
D O I
10.3390/scipharm90040058
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
(1) Background: Hepatotoxicity is a common health problem, and oxidative stress plays a crucial role in its underlying mechanisms. We inspected the possible effect of retinoic acid (RA) in the potentiation of hepatoprotective effect of bone marrow mesenchymal stem cells (BM-MSCs) against Cisplatin (Cis)-induced hepatotoxicity. (2) Methods: 60 male Sprague Dawley rats (SD) were separated randomly and designated to six main equal groups as follows: (1) Control group, (2) Cis group (rats got Cis 7 mg/Kg i.p.), (3) Cis + vehicle group (as group 2, but rats received the (vehicle) culture media of BM-MSCs), (4) Cis as in group 2 + BM-MSCs (1x10(6)), (5) Cis as for group 2 + RA 1 mg/Kg i.p., and (6) Cis and BM-MSCs as for group 3 + RA as for group 4. Liver injury was assessed by measuring liver enzymes (ALT, AST), while liver toxicity was evaluated by histopathological examination. Apoptotic marker caspase-3 protein was detected immunohistochemically. Real time PCR was performed to detect NADPH oxidase and TNF-alpha at transcription levels. Oxidative stress was investigated by colorimetric measurement of MDA, GSH and catalase. (3) Results: Contrary to the Cis group (p < 0.05), BM-MSCs/RA supplementation resulted in a substantial decrease in serum levels of hepatic impairment indicators such as ALT, AST and oxidative stress markers such as MDA, as well as an increase in hepatic GSH, Catalase, and a decrease in expression of TNF-alpha and downregulation of NADPH oxidase. The improvement after therapy with BM-MSCs/RA was confirmed by histopathological examination. Moreover, the downregulation of caspase-3 in liver tissue after BM-MSCs/RA treatment was validated by immunohistochemistry investigation. (4) Conclusions: BM-MSCs and RA attenuated Cis induced hepatotoxicity through downregulation of oxidative stress resulted in modulation of anti-inflammatory TNF-alpha and apoptosis caspase-3 indicating a promising role in hepatotoxicity.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Icariin stimulates differentiation of bone marrow-derived mesenchymal stem cells (BM-MSCs) through activation of cAMP/PKA/CREB
    Lou, Dan
    Ye, Jifeng
    Yang, Lianhua
    Wu, Zheng
    Zheng, Wei
    Zhang, Hui
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 55
  • [2] Bone marrow-derived mesenchymal stem cells protect against cisplatin-induced acute kidney injury in rats by inhibiting cell apoptosis
    Qi, Shaohua
    Wu, Dongcheng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 32 (06) : 1262 - 1272
  • [3] Reciprocal Effect of Environmental Stimuli to Regulate the Adipogenesis and Osteogenesis Fate Decision in Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)
    Xu, Xinyun
    Zhao, Ling
    Terry, Paul D.
    Chen, Jiangang
    CELLS, 2023, 12 (10)
  • [4] Potentiality of Bone Marrow-Derived Mesenchymal Stromal Cells (BM-MSCs) to Differentiate into the Osteogenic Lineage in in Vitro Model of Tissue Regeneration
    Re, Federica
    Sartore, Luciana
    Borsani, Elisa
    Ferroni, Matteo
    Pasini, Chiara
    Pandini, Stefano
    Bernardi, Simona
    Bosio, Katia
    Mutti, Silvia
    Cavalleri, Alessia
    Leoni, Alessandro
    Polverelli, Nicola
    Morello, Enrico
    Farina, Mirko
    Radici, Vera
    Malagola, Michele
    Russo, Domenico
    BLOOD, 2023, 142
  • [5] Bone marrow-derived mesenchymal stem cells (BM-MSCs) inhibit apoptosis of spinal cord cells in a kaolin-induced syringomyelia-associated scoliosis rabbit model
    Zhao, Zhi
    Xu, Wei
    Xie, Jingming
    Wang, Yingsong
    Li, Tao
    Zhang, Ying
    Zhao, Daohong
    Bi, Ni
    Shi, Zhiyue
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (04): : 1890 - 1899
  • [6] Beetroot Improves the Therapeutic Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells in Preventing Cisplatin Induced Nephrotoxicity in Male Rats
    Morsy, Wafaa A.
    Kadry, Shadia M.
    Hassen, Marwa T.
    Abd El-Motelp, Bosy Azmy
    BIOINTERFACE RESEARCH IN APPLIED CHEMISTRY, 2023, 13 (01):
  • [7] Acidic PH inhibits the stiffness response in human bone marrow mesenchymal stem cells (BM-MSCS)
    Usta, Yusuf Hakan
    Lawless, Craig
    Swift, Joe
    Richardson, Stephen
    Gilbert, Hamish
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2023, 104 (02) : A19 - A19
  • [8] CHONDROGENIC DIFFERENTIATION OF BONE MARROW MESENCHYMAL STEM CELLS (BM-MSCS) GROWN ON COLLAGEN POROUS SCAFFOLDS
    Diaz-Prado, S.
    Muinos-Lopez, E.
    Hermida-Gomez, T.
    Fuentes, I. M.
    Esbrit, P.
    Bujan, J.
    De Toro, F. J.
    Blanco, F. J.
    OSTEOARTHRITIS AND CARTILAGE, 2011, 19 : S221 - S221
  • [9] Acidic pH inhibits the stiffness response of human bone-marrow mesenchymal stem cells (BM-MSCs)
    Usta, Yusuf Hakan
    Swift, Joe
    Gilbert, Hamish T. J.
    Richardson, Stephen M.
    TISSUE ENGINEERING PART A, 2023, 29 (13-14)
  • [10] Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells (BM-MSCS) from patients with hematological disorders: Correlation with culture conditions and bone marrow microenvironment.
    Campioni, D.
    Moretti, S.
    Ferrari, L.
    Dominici, M.
    Lanza, F.
    CYTOTHERAPY, 2006, 8